Lipinski's rule of five predicts the oral bioavailability of a drug candidate based on molecular properties. The rule suggests that good oral drugs generally have no more than one violation among these: not more than 5 hydrogen bond donors, 10 hydrogen bond acceptors, molecular weight under 500 Da, and logP not greater than 5.